Published in J Virol on August 01, 2003
Oxidase-deficient neutrophils from X-linked chronic granulomatous disease iPS cells: functional correction by zinc finger nuclease-mediated safe harbor targeting. Blood (2011) 3.21
Site-specific integration and tailoring of cassette design for sustainable gene transfer. Nat Methods (2011) 2.30
Safe harbours for the integration of new DNA in the human genome. Nat Rev Cancer (2011) 1.67
Adeno-associated virus: from defective virus to effective vector. Virol J (2005) 1.60
Zinc-finger nucleases for somatic gene therapy: the next frontier. Hum Gene Ther (2011) 1.11
A simple and efficient system for regulating gene expression in human pluripotent stem cells and derivatives. Stem Cells (2014) 1.00
An AAVS1-targeted minigene platform for correction of iPSCs from all five types of chronic granulomatous disease. Mol Ther (2014) 1.00
Efficient recombinase-mediated cassette exchange at the AAVS1 locus in human embryonic stem cells using baculoviral vectors. Nucleic Acids Res (2011) 0.98
Stable enhanced green fluorescent protein expression after differentiation and transplantation of reporter human induced pluripotent stem cells generated by AAVS1 transcription activator-like effector nucleases. Stem Cells Transl Med (2014) 0.92
Efficient Recombinase-Mediated Cassette Exchange in hPSCs to Study the Hepatocyte Lineage Reveals AAVS1 Locus-Mediated Transgene Inhibition. Stem Cell Reports (2015) 0.92
Genomic editing tools to model human diseases with isogenic pluripotent stem cells. Stem Cells Dev (2014) 0.89
Efficient derivation and genetic modifications of human pluripotent stem cells on engineered human feeder cell lines. Stem Cells Dev (2012) 0.88
A small regulatory element from chromosome 19 enhances liver-specific gene expression. Gene Ther (2008) 0.87
Baculoviral transduction facilitates TALEN-mediated targeted transgene integration and Cre/LoxP cassette exchange in human-induced pluripotent stem cells. Nucleic Acids Res (2013) 0.87
Gene correction in patient-specific iPSCs for therapy development and disease modeling. Hum Genet (2016) 0.83
Generation of GFP Reporter Human Induced Pluripotent Stem Cells Using AAVS1 Safe Harbor Transcription Activator-Like Effector Nuclease. Curr Protoc Stem Cell Biol (2014) 0.81
Transfection, selection, and colony-picking of human induced pluripotent stem cells TALEN-targeted with a GFP gene into the AAVS1 safe harbor. J Vis Exp (2015) 0.77
Multidimensional Genome-wide Analyses Show Accurate FVIII Integration by ZFN in Primary Human Cells. Mol Ther (2015) 0.77
Targeted introduction and effective expression of hFIX at the AAVS1 locus in mesenchymal stem cells. Mol Med Rep (2017) 0.75
Nuclease hypersensitive sites in chromatin. Annu Rev Biochem (1988) 13.48
The protein CTCF is required for the enhancer blocking activity of vertebrate insulators. Cell (1999) 9.74
Site-specific integration by adeno-associated virus. Proc Natl Acad Sci U S A (1990) 7.06
Meiotic chromosomes: it takes two to tango. Genes Dev (1997) 6.90
Integration of the adeno-associated virus genome into cellular DNA in latently infected human Detroit 6 cells. J Virol (1980) 5.09
Epstein-Barr virus-derived plasmids replicate only once per cell cycle and are not amplified after entry into cells. J Virol (1991) 4.46
Characterization of a preferred site on human chromosome 19q for integration of adeno-associated virus DNA by non-homologous recombination. EMBO J (1992) 4.36
Herpes simplex virus types 1 and 2 completely help adenovirus-associated virus replication. J Virol (1981) 3.72
Loss of transcriptional activity of a transgene is accompanied by DNA methylation and histone deacetylation and is prevented by insulators. Genes Dev (1998) 3.70
Characterization of the chicken beta-globin insulator. Proc Natl Acad Sci U S A (1997) 3.57
Mapping and direct visualization of a region-specific viral DNA integration site on chromosome 19q13-qter. Genomics (1991) 3.47
Structural and functional conservation at the boundaries of the chicken beta-globin domain. EMBO J (2000) 2.88
Adeno-associated viruses: an update. Adv Virus Res (1987) 2.71
The insulation of genes from external enhancers and silencing chromatin. Proc Natl Acad Sci U S A (2002) 2.60
Establishment and characterization of KB cell lines latently infected with adeno-associated virus type 1. Virology (1977) 2.53
Adeno-associated virus autointerference. Virology (1979) 2.43
Biology of adeno-associated virus. Curr Top Microbiol Immunol (1996) 2.40
DNA amplification of adeno-associated virus as a response to cellular genotoxic stress. Cancer Res (1988) 2.39
A cascade of adenovirus early functions is required for expression of adeno-associated virus. Cell (1981) 2.33
Site-specific integration by adeno-associated virus is directed by a cellular DNA sequence. Proc Natl Acad Sci U S A (1994) 2.25
Analysis of proteins, helper dependence, and seroepidemiology of a new human parvovirus. Virology (1984) 2.13
Adeno-associated virus Rep proteins target DNA sequences to a unique locus in the human genome. J Virol (1997) 2.06
Recombinant junctions formed by site-specific integration of adeno-associated virus into an episome. J Virol (1995) 2.02
The barrier function of an insulator couples high histone acetylation levels with specific protection of promoter DNA from methylation. Genes Dev (2002) 1.89
A subset of herpes simplex virus replication genes provides helper functions for productive adeno-associated virus replication. J Virol (1991) 1.56
Hypersensitive site 5 of the human beta locus control region functions as a chromatin insulator. Blood (1994) 1.52
Human cytomegalovirus completely helps adeno-associated virus replication. Virology (1985) 1.39
Gene expression in adeno-associated virus vectors: the effects of chimeric mRNA structure, helper virus, and adenovirus VA1 RNA. Virology (1987) 1.35
Position-independent transgene expression mediated by boundary elements from the apolipoprotein B chromatin domain. Mol Cell Biol (1995) 1.26
Characteristics of the adeno-associated virus preintegration site in human chromosome 19: open chromatin conformation and transcription-competent environment. J Virol (2000) 1.12
Kinetics and frequency of adeno-associated virus site-specific integration into human chromosome 19 monitored by quantitative real-time PCR. J Virol (2002) 1.08
Adeno-associated virus DNA replication is induced by genes that are essential for HSV-1 DNA synthesis. Virology (1990) 1.01
The gypsy insulator of Drosophila affects chromatin structure in a directional manner. Genetics (2001) 0.90
In vivo analysis of chromatin structure. Methods Enzymol (1999) 0.85
Rescue of AAV by antibody-induced Fas-mediated apoptosis from viral DNA integrated in HeLa chromosome. Virology (2002) 0.81
Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: can SBRT be comparable to surgery? Int J Radiat Oncol Biol Phys (2010) 3.66
Two novel adeno-associated viruses from cynomolgus monkey: pseudotyping characterization of capsid protein. Virology (2004) 1.88
Late toxicity after definitive concurrent chemoradiotherapy for thoracic esophageal carcinoma. Int J Radiat Oncol Biol Phys (2009) 1.40
Identification of monomorphic and divergent haplotypes in the 2006-2007 norovirus GII/4 epidemic population by genomewide tracing of evolutionary history. J Virol (2008) 1.26
Biased amplification of human papillomavirus DNA in specimens containing multiple human papillomavirus types by PCR with consensus primers. Cancer Sci (2011) 1.13
Human scribble, a novel tumor suppressor identified as a target of high-risk HPV E6 for ubiquitin-mediated degradation, interacts with adenomatous polyposis coli. Genes Cells (2006) 1.13
Mutational analysis of human papillomavirus type 16 major capsid protein L1: the cysteines affecting the intermolecular bonding and structure of L1-capsids. Virology (2003) 1.08
Safety and immunogenicity of a peptide containing the cross-neutralization epitope of HPV16 L2 administered nasally in healthy volunteers. Vaccine (2003) 1.07
Net positive charge of HIV-1 CRF01_AE V3 sequence regulates viral sensitivity to humoral immunity. PLoS One (2008) 1.07
Divergent evolution of norovirus GII/4 by genome recombination from May 2006 to February 2009 in Japan. J Virol (2010) 1.07
Human papillomavirus 16 minor capsid protein L2 helps capsomeres assemble independently of intercapsomeric disulfide bonding. Virus Genes (2005) 1.04
Involvement of a cellular ubiquitin-protein ligase E6AP in the ubiquitin-mediated degradation of extensive substrates of high-risk human papillomavirus E6. J Med Virol (2006) 1.01
Modification of human papillomavirus-like particle vaccine by insertion of the cross-reactive L2-epitopes. J Med Virol (2008) 1.01
Irinotecan plus cisplatin for therapy of small-cell carcinoma of the esophagus: report of 12 cases from single institution experience. Jpn J Clin Oncol (2008) 0.97
Dosimetric consideration of individual 125I source strength measurement and a large-scale comparison of that measured with a nominal value in permanent prostate implant brachytherapy. Radiat Med (2006) 0.95
Antibody-dependent enhancement of adeno-associated virus infection of human monocytic cell lines. Virology (2008) 0.93
Inhibition of nuclear entry of HPV16 pseudovirus-packaged DNA by an anti-HPV16 L2 neutralizing antibody. Virology (2010) 0.92
Genotype distribution of human papillomaviruses in Japanese women with abnormal cervical cytology. Open Virol J (2012) 0.91
Biodistribution of a low dose of intravenously administered AAV-2, 10, and 11 vectors to cynomolgus monkeys. Jpn J Infect Dis (2006) 0.90
CCAAT/enhancer binding protein beta binds to and activates the P670 promoter of human papillomavirus type 16. Virology (2005) 0.89
Treatment of thoracic esophageal carcinoma invading adjacent structures. Cancer Sci (2007) 0.88
Monoclonal antibodies recognizing cross-neutralization epitopes in human papillomavirus 16 minor capsid protein L2. Virology (2012) 0.87
A pilot study of wider use of accelerated partial breast irradiation: intraoperative margin-directed re-excision combined with sole high-dose-rate interstitial brachytherapy. Breast Cancer (2006) 0.85
Neutralizing antibodies against human papillomavirus types 16, 18, 31, 52, and 58 in serum samples from women in Japan with low-grade cervical intraepithelial neoplasia. Clin Vaccine Immunol (2008) 0.85
Preliminary study of correction of original metal artifacts due to 1-125 seeds in postimplant dosimetry for prostate permanent implant brachytherapy. Radiat Med (2006) 0.84
Patterns of practice in intensity-modulated radiation therapy and image-guided radiation therapy for prostate cancer in Japan. Jpn J Clin Oncol (2011) 0.84
Rolling circle replication of human papillomavirus type 16 DNA in epithelial cell extracts. Genes Cells (2010) 0.83
Thiol-reactive reagents inhibits intracellular trafficking of human papillomavirus type 16 pseudovirions by binding to cysteine residues of major capsid protein L1. Virol J (2007) 0.83
Structural basis for specific recognition of substrates by sapovirus protease. Front Microbiol (2012) 0.83
Nuclear location of minor capsid protein L2 is required for expression of a reporter plasmid packaged in HPV51 pseudovirions. Virology (2009) 0.82
Rescue of AAV by antibody-induced Fas-mediated apoptosis from viral DNA integrated in HeLa chromosome. Virology (2002) 0.81
Dose-escalation study of three-dimensional conformal thoracic radiotherapy with concurrent S-1 and cisplatin for inoperable stage III non-small-cell lung cancer. Clin Lung Cancer (2013) 0.80
IgG antibodies to human papillomavirus 16, 52, 58, and 6 L1 capsids: case-control study of cervical intraepithelial neoplasia in Japan. J Med Virol (2003) 0.80
Evidence for the presence of neutralizing antibodies against human papillomavirus type 6 in infants born to mothers with condyloma acuminata. Am J Perinatol (2003) 0.79
IgG antibodies to HPV16, 52, 58 and 6 L1-capsids and spontaneous regression of cervical intraepithelial neoplasia. Cancer Lett (2006) 0.79
Identification of folding preferences of cleavage junctions of HIV-1 precursor proteins for regulation of cleavability. J Mol Model (2010) 0.79
Enhanced transgene expression in the mouse skeletal muscle infected by the adeno-associated viral vector with the human elongation factor 1alpha promoter and a human chromatin insulator. J Gene Med (2009) 0.78
In vivo dosimetry of high-dose-rate interstitial brachytherapy in the pelvic region: use of a radiophotoluminescence glass dosimeter for measurement of 1004 points in 66 patients with pelvic malignancy. Int J Radiat Oncol Biol Phys (2007) 0.78
Inhibitory cis-element-mediated decay of human papillomavirus type 16 L1-transcript in undifferentiated cells. Mol Cell Biochem (2006) 0.78
Identification of nucleolin as a protein that binds to human papillomavirus type 16 DNA. Biochem Biophys Res Commun (2009) 0.78
Characterization of mouse 3T3-swiss albino cells available in Japan: necessity of quality control when used as feeders. Jpn J Infect Dis (2008) 0.78
Human papillomavirus type 16 P670 promoter is negatively regulated by CCAAT displacement protein. Virus Genes (2007) 0.77
Neutralizing antibodies against oncogenic human papillomavirus as a possible determinant of the fate of low-grade cervical intraepithelial neoplasia. Biochem Biophys Res Commun (2002) 0.77
Transcription factor human Skn-1a enhances replication of human papillomavirus DNA through the direct binding to two sites near the viral replication origin. FEBS J (2008) 0.77
Genes up- or down-regulated by expression of keratinocyte-specific POU transcription factor hSkn-1a. Biochem Biophys Res Commun (2003) 0.77
Early onset recall pneumonitis during targeted therapy with sunitinib. BMC Cancer (2013) 0.76
Do neutralizing antibody responses generated by human papillomavirus infections favor a better outcome of low-grade cervical lesions? J Med Virol (2012) 0.76
High-dose-rate interstitial brachytherapy for gynecologic malignancies--dosimetric changes during treatment period. J Radiat Res (2013) 0.75
Keratinocyte-specific POU transcription factor hSkn-1a represses the growth of cervical cancer cell lines. Oncogene (2004) 0.75
Longitudinal change in health-related quality of life after intensity-modulated radiation monotherapy for clinically localized prostate cancer. Qual Life Res (2013) 0.75
[Development of stereotactic irradiation system of body tumors under respiratory gating]. Nihon Igaku Hoshasen Gakkai Zasshi (2002) 0.75
[Optimal parameter decision method in VMAT for lung tumors with respiratory motions]. Nihon Hoshasen Gijutsu Gakkai Zasshi (2015) 0.75
Long-term oncological outcome in men with T3 prostate cancer: radical prostatectomy versus external-beam radiation therapy at a single institution. Int J Clin Oncol (2013) 0.75
An adeno-associated virus vector efficiently and specifically transduces mouse skeletal muscle. Mol Biotechnol (2011) 0.75